This article is transferred from: National Party Media Information Public Platform
Source: People’s Daily Health Client
Vaccine Highlights
< p>The cost of the new coronavirus vaccine is more than 120 billion yuan
On April 2, the National Medical Insurance Administration stated that at present, my country has vaccinated 3.2 billion doses of the vaccine, and the vaccine cost more than 120 billion yuan Yuan, which is shared by the medical insurance fund and the finance, and the cost of vaccine expenditure is within the affordable range of the medical insurance fund. (National Medical Insurance Administration)
Pfizer and Moderna’s fourth dose of new crown vaccine is authorized for emergency use
On March 29, Pfizer issued an announcement saying, The new crown vaccine jointly developed with BioNTech has been authorized by the FDA to expand its emergency use scope. Certain groups of people can receive a second booster dose of this vaccine, and the second booster vaccine injection time and the first dose should be at least four months apart. These groups include: people 50 years and older; immunocompromised people 12 years and older. (Sina Pharmaceutical News)
R&D News
Researchers from the Chinese Academy of Biological Sciences in the laboratory. According to the official website of China Biotechnology
The second-generation recombinant protein new crown vaccine of China Biotechnology has been approved for clinical use
On April 3, the official website of Sinopharm Group China announced that , its second-generation recombinant protein new crown vaccine obtained the clinical trial approval document issued by the State Drug Administration. According to relevant clinical trial data, the second-generation recombinant protein new crown vaccine has shown good effects on mutant strains such as Omicron. (People’s Daily Health Client)
Vaccine Industry
Rec Bio listed on the Hong Kong Stock Exchange
On March 31, Ruike Bio was officially listed on the Hong Kong Stock Exchange. Priced at HK$24.80 per share, with lots of 500 shares. Ruike Bio has successfully achieved the independent control of all new FDA-approved adjuvants, and has been successfully applied to a number of innovative vaccines such as the new crown vaccine, HPV vaccine and shingles vaccine. (According to the company announcement)
(Vaccine channel submission, industry communication email [email protected])
Editor in charge: Zhu Xiaona proofreading: Lu Yang
This article is from [ People’s Daily Health Client], only represents the author’s point of view. The national party media information public platform provides information release and dissemination services.
ID: jrtt